A group of scientists from the French National Center for Scientific Research (CNRS) have overturned a scientific dogma by demonstrating, for the first time, that DNA mutations are not essential for the development of cancer. The researchers temporarily disrupted gene silencing led by Polycomb proteins in fruit flies, and observed that this could produce tumors caused only by epigenetic changes, without permanent changes to the genome. Read More
Researchers from State University of New Jersey (Rutgers) and Oklahoma State University have published preclinical data for a novel a SARS-CoV-2 papain-like protease (PLpro) inhibitor being developed as an antiviral candidate for the treatment of COVID-19. Read More
Severe fever with thrombocytopenia syndrome (SFTS) is a tick-borne disease that results from an infection with the SFTS virus, with a case fatality rate of 6.1% to 21.8%. Identifying critically ill patients at the early stages is crucial for clinical management. Read More
Replay Holdings LLC and The University of Texas MD Anderson Cancer Center report that the FDA has cleared the IND application for PRAME TCR/IL-15 NK (SY-307), an engineered T-cell receptor natural killer (TCR-NK) cell therapy for relapsed/refractory myeloid malignancies. Read More
Peptidream Inc. and Novartis Pharma AG have expanded their peptide-drug conjugate discovery collaboration announced in 2019, adding additional peptide radioligand therapies and other programs. Read More
Researchers from Axcynsis Therapeutics Pte. Ltd. presented the development and preclinical characterization of AT-2604, a novel antibody-drug conjugate (ADC) targeting the placental alkaline phosphatases, ALPP and ALPPL2. Read More
Chong Kun Dang Pharm (CKD Pharm) has presented data on their c-Met-targeting antibody-drug conjugate (ADC) CKD-703 for the treatment of solid tumors. CKD-703 was designed based on site-specific conjugation, with a stable and homogeneous drug-antibody ratio profile. Read More
Work at Bellbrook Labs LLC has led to the discovery of imidazolyl-alkoxyquinolin-2-amines acting as cyclic GMP-AMP synthase (MB21D1; cGAS) inhibitors. Read More
A Jaguahr Therapeutics Pte Ltd. patent describes new aryl hydrocarbon receptor (AhR) antagonists reported to be useful for the treatment of cancer. Read More
Repertoire Immune Medicines Inc. has entered a multiyear strategic collaboration with Bristol Myers Squibb Co. (BMS) to develop tolerizing vaccines for up to three autoimmune diseases. Read More
